Press Releases

Immudyne Announces Successful National Launch of Shapiro MD Hair Loss Product Line

MT. KISCO, N.Y., June 07, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, is pleased to announce a successful national launch of our patented Shapiro MD product line. 

Within the first several weeks of the product’s launch on Facebook, Immudyne sold all available inventory. Our entire team and supply chain partners have been working diligently to increase production and inventory levels for the product, and we’re pleased to report that as of today we have sufficient inventory levels to considerably scale the Shapiro MD business.

“Although we had and continue to have big expectations for the Shapiro MD line, the initial success of our marketing efforts exceeded everyone’s expectations,” stated Justin Schreiber, President of Immudyne PR. “I believe that the success of this product launch reinforces Immudyne PR’s business model of in-licensing high quality consumer products in large addressable markets that can be scaled through online marketing channels such as Facebook, Google and Amazon.”

The Shapiro MD product line is the result of 15 years of research and development by thought-leading dermatologists Dr. Steven Shapiro and Dr. Michael Borenstein.  It is protected by two U.S. patents and is the only product in the hair loss vertical that contains what we believe are the 3 most powerful, naturally-occurring dihydrotestosterone (DHT) blocking ingredients.  DHT is widely believed to be the main culprit of balding/hair-loss.

In addition to the Shampoo and Conditioner, Immudyne PR has formulated a once-daily leave in foam and is finalizing the formulation of a nutritional supplement. We believe both products will be a strong addition to the product line and should be available within the next 90 days.

“The amount of inbound inquiries we’ve received on Shapiro MD within the first several weeks of launch is off-the-charts,” stated Mark McLaughlin, Chief Executive Officer of Immudyne. “We’re very excited about the potential of the line and are now laser-focused on scaling inventory levels and optimizing our infrastructure to permit profitable revenue growth around the world.”    

The global alopecia (hair loss) market is expected to reach USD 11.8 Billion by 2024 according to a recent report published by independent research firm, Grand View Research, Inc.

For more information on Shapiro MD or to purchase the product, please visit www.shapiromd.com.

About lmmuDyne

lmmuDyne, Inc. (the "Company") is a health and wellness company that develops, manufactures, and markets innovative consumer products. Immudyne manufactures and markets a proprietary and patent protected Yeast Beta Glucan that has been shown in thousands of clinical studies to support and regulate the human immune system.  It has broad applications in skincare and as an immune support supplement.  Immudyne PR, a majority owned subsidiary of ImmuDyne, Inc., is the digital marketing arm of Immudyne and is currently focused on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing Immudyne’s proprietary Yeast Beta Glucan ingredient (Inate MD).  All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.

Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward­ looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans,"  "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901

Source: ImmuDyne, Inc.